JP2010510216A - プロテインキナーゼのインヒビターとして有用な化合物 - Google Patents

プロテインキナーゼのインヒビターとして有用な化合物 Download PDF

Info

Publication number
JP2010510216A
JP2010510216A JP2009537209A JP2009537209A JP2010510216A JP 2010510216 A JP2010510216 A JP 2010510216A JP 2009537209 A JP2009537209 A JP 2009537209A JP 2009537209 A JP2009537209 A JP 2009537209A JP 2010510216 A JP2010510216 A JP 2010510216A
Authority
JP
Japan
Prior art keywords
ring
compound
independently
groups
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009537209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510216A5 (enExample
Inventor
ロナルド ネグテル，
ジャン−ダミアン シャリエ，
スティーブン デュラント，
ガイ ブレンチリー，
マイケル モーティモア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2010510216A publication Critical patent/JP2010510216A/ja
Publication of JP2010510216A5 publication Critical patent/JP2010510216A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
JP2009537209A 2006-11-15 2007-11-15 プロテインキナーゼのインヒビターとして有用な化合物 Pending JP2010510216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85911306P 2006-11-15 2006-11-15
US98414907P 2007-10-31 2007-10-31
PCT/US2007/023999 WO2008060597A2 (en) 2006-11-15 2007-11-15 Compounds useful as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2010510216A true JP2010510216A (ja) 2010-04-02
JP2010510216A5 JP2010510216A5 (enExample) 2011-12-15

Family

ID=39402262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537209A Pending JP2010510216A (ja) 2006-11-15 2007-11-15 プロテインキナーゼのインヒビターとして有用な化合物

Country Status (10)

Country Link
US (3) US7838517B2 (enExample)
EP (1) EP2094712B1 (enExample)
JP (1) JP2010510216A (enExample)
AT (1) ATE528309T1 (enExample)
AU (1) AU2007319786A1 (enExample)
CA (1) CA2669886A1 (enExample)
ES (1) ES2372320T3 (enExample)
MX (1) MX2009005231A (enExample)
NZ (1) NZ576950A (enExample)
WO (1) WO2008060597A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511410A (ja) * 2016-12-12 2020-04-16 レオ ファーマ アクティーゼルスカブ 置換ピラゾロアゼピン−４−オンおよびそれらのホスホジエステラーゼ阻害剤としての使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
WO2008060597A2 (en) 2006-11-15 2008-05-22 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
EA019980B1 (ru) 2009-12-18 2014-07-30 Янссен Фармацевтика Нв БИЦИКЛИЧЕСКИЕ ТИАЗОЛЫ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR5
WO2011073347A1 (en) 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mglur5 receptors
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
ES2874632T3 (es) 2016-12-12 2021-11-05 Union Therapeutics As Pirazoloazepin-8-onas sustituidas y su uso como inhibidores de la fosfodiesterasa
RU2762279C2 (ru) 2016-12-12 2021-12-17 Юнион Терапьютикс А/С Замещенные пиразолоазепин-4-оны и их применение в качестве ингибиторов фосфодиэстеразы

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514043A (ja) * 2002-12-20 2006-04-27 ファルマシア・コーポレーション マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−２を阻害する化合物
WO2006114606A1 (en) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH632755A5 (de) 1976-04-10 1982-10-29 Basf Ag Verfahren zur herstellung von thiophenverbindungen.
US5206240A (en) 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
WO1993013105A1 (en) 1991-12-26 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
JP2007529422A (ja) 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ， インコーポレイテッド 抗ウイルス治療
WO2008060597A2 (en) 2006-11-15 2008-05-22 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514043A (ja) * 2002-12-20 2006-04-27 ファルマシア・コーポレーション マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−２を阻害する化合物
WO2006114606A1 (en) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013021200; ＳＴＥＰＡＮＯＶ，Ｄ．Ｅ．　ｅｔ　ａｌ: 'Ｎｅｗ　ｄｅｒｉｖａｔｉｖｅｓ　ｏｆ　４，５，６，７-ｔｅｔｒａｈｙｄｒｏｂｅｎｚｏｔｈｉａｚｏｌ-７-ｏｎｅ　ａｎｄ　５，６，７，８-ｔｅｔｒａｈｙｄｒｏ-４Ｈ-ｔｈｉａｚｏｌｏ［５，４-ｃ］ａｚｅ' Ｒｕｓｓｉａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｇｅｎｅｒａｌ　Ｃｈｅｍｉｓｔｒｙ（Ｔｒａｎｓｌａｔｉｏｎ　ｏｆ　Ｚｈｕｒｎａｌ　Ｏｂｓｈｃｈｅｉ　Ｋｈｉｍｉｉ） Ｖｏｌ．７０，　Ｎｏ．５, 2000, ｐ．７８４-７８７ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511410A (ja) * 2016-12-12 2020-04-16 レオ ファーマ アクティーゼルスカブ 置換ピラゾロアゼピン−４−オンおよびそれらのホスホジエステラーゼ阻害剤としての使用
JP7008073B2 (ja) 2016-12-12 2022-01-25 ユニオン・セラピューティクス・アクティエセルスカブ 置換ピラゾロアゼピン－４－オンおよびそれらのホスホジエステラーゼ阻害剤としての使用

Also Published As

Publication number Publication date
WO2008060597A3 (en) 2008-09-25
ATE528309T1 (de) 2011-10-15
NZ576950A (en) 2012-01-12
US7838517B2 (en) 2010-11-23
EP2094712B1 (en) 2011-10-12
WO2008060597A8 (en) 2009-07-23
WO2008060597A2 (en) 2008-05-22
ES2372320T3 (es) 2012-01-18
US20090281082A1 (en) 2009-11-12
CA2669886A1 (en) 2008-05-22
US8399458B2 (en) 2013-03-19
AU2007319786A1 (en) 2008-05-22
US20130267498A1 (en) 2013-10-10
MX2009005231A (es) 2009-06-19
US20120028965A1 (en) 2012-02-02
EP2094712A2 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
EP2102210B1 (en) Compounds useful as protein kinase inhibitors
JP5498703B2 (ja) プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド
EP2007757B1 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009538309A (ja) プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
US8399458B2 (en) Compounds useful as protein kinase inhibitors
JP2009538305A (ja) プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
HK1137013A (en) Compounds useful as protein kinase inhibitors
HK1134285A (en) Thiophene-carboxamides useful as inhibitors or protein kinases
HK1125932A (en) Thiophene-carboxamides useful as inhibitors of protein kinases
AU2013200105A1 (en) Thiophene-carboxamides useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131004